Foghorn Therapeutics Inc.
FHTXNASDAQHealthcare● Active
$3.71
$-0.02(-0.54%)
Market Cap$217828569
P/E Ratio—
52W High$6.95
52W Low$3.27
Foghorn Therapeutics Inc. (FHTX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · FHTX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $30.91M | $22.60M | $34.16M | $19.23M | $1.32M |
| Cost of Revenue | $3.33M | $0.00M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $27.58M | $22.60M | $34.16M | $19.23M | $1.32M |
| Gross Margin %(computed) | 89.22% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $85.47M | $94.53M | $109.69M | $105.62M | $80.33M |
| G&A Expenses | $27.55M | $28.36M | $32.37M | $30.75M | $21.73M |
| Total Operating Expenses | $109.68M | $125.28M | $142.06M | $136.37M | $102.05M |
| Operating Income | ($82.11M) | ($102.68M) | ($107.91M) | ($117.14M) | ($100.73M) |
| Operating Margin %(computed) | -265.64% | -454.31% | -315.93% | -609.20% | — |
| Interest Income | $8.74M | $11.90M | $10.88M | $5.67M | $0.06M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $1.91M |
| Income Before Tax | ($74.28M) | ($86.62M) | ($94.20M) | ($108.88M) | ($101.32M) |
| Income Tax Expense | $0.00M | $0.00M | $4.23M | $0.00M | $0.00M |
| Net Income | ($74.28M) | ($86.62M) | ($98.43M) | ($108.88M) | ($101.32M) |
| Net Margin %(computed) | -240.33% | -383.24% | -288.17% | -566.27% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.18 | $-1.58 | $-2.34 | $-2.62 | $-2.78 |
| Wtd Avg Shares | 62.98M | 54.90M | 41.97M | 41.59M | 37.17M |
| EBITDA | ($78.78M) | ($97.17M) | ($104.45M) | ($113.82M) | ($96.19M) |
| EBITDA Margin %(computed) | -254.86% | -429.90% | -305.83% | -591.93% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Foghorn Therapeutics Inc. data
About Foghorn Therapeutics Inc. (FHTX) Income Statement
Foghorn Therapeutics Inc. (FHTX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, FHTX reported revenue of $0.03B, gross profit of $0.03B (gross margin 89.22%), and net income of ($0.07B) — a net profit margin of -240.33%.
Frequently asked questions
FHTX · 4 questionsFoghorn Therapeutics Inc. (FHTX) reported revenue of $0.03B for 2025, up 36.8% year-over-year.
FHTX revenueFHTX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08